The level of response was measured according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 by investigator assessment.
The treatment response rate was the percentage of patients with complete or partial response.
The response rate was assessed only for 198 (out of 237) and 190 (out of 222) patients in the SIRT and sorafenib arms respectively.
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.